SecBot SecBot
8-K ·Filed Aug 12, 2026

NERV

Minerva Neurosciences, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001193125-26-346817
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No trading signal. This is a routine internal accounting role consolidation. Monitor for any future CFO departure or broader C-suite changes, but this filing alone is administrative.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
NERV ▲ +5.87% at T+20d
NEUTRAL call +5.87% · α vs SPY +7.61% · entry $3.92 → $4.15
Next anchor: T+60d in 10d
Latest observation: T+50 -19.16% FF3 residual α
Entry = T+0 close
Aug 12, 2026
via day close
T+1d
+16.84%
call +16.84% · α +17.03%
$4.58
settled 2mo ago
T+5d
+22.19%
call +22.19% · α +24.16%
$4.79
settled 2mo ago
T+20d
+5.87%
call +5.87% · α +7.61%
$4.15
settled 7w ago
T+60d
Pending
in 10d

Price Chart

Loading chart...

Executive Summary

Minerva Neurosciences appointed Anthony Aliquo as Chief Accounting Officer, relieving CFO Fred Ahlholm of the principal accounting officer role. Ahlholm remains CFO. This is an internal promotion with no red flags — a routine administrative change with no material financial impact.

Key Facts

  • Anthony Aliquo appointed Chief Accounting Officer effective August 10, 2026
  • CFO Fred Ahlholm ceased serving as principal accounting officer but remains CFO
  • Aliquo's annual base salary increased to $296,696, bonus target set at 35% of base salary
  • Aliquo has served as VP, Controller since November 2022 and previously as Controller and Assistant Controller
  • No family relationships or material transactions involving Aliquo

Financial Impact

No material financial impact — compensation increase for internal promotion is routine

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-346817
Document: 0001193125-26-346817-index-headers.html0001193125-26-346817
Document: 0001193125-26-346817-index.html0001193125-26-346817
Document: 0001193125-26-346817.txt0001193125-26-346817
9 reports for NERV
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NERV — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$3.92awaiting T+60—$2.20 (−43.88%)
Aug 7, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$4.27awaiting T+60—$2.20 (−48.48%)
May 27, 2026
21w ago
8-K
BEARISH ★ 6/10
$5.00 $4.84▲ +3.20%▲ +4.93%$2.20 (+56.00%)
May 5, 2026
24w ago
8-K
NEUTRAL ★ 4/10
$6.25 $4.02▼ −35.68%▼ −38.42%$2.20 (−64.80%)
Apr 23, 2026
26w ago
DEFA14A
NEUTRAL ★ 4/10
$6.83 $4.37▼ −36.02%▼ −41.04%$2.20 (−67.79%)
Mar 25, 2026
30w ago
Press Release
NEUTRAL ★ 5/10
$6.14 $4.66▼ −24.10%▼ −38.05%$2.20 (−64.17%)
Mar 20, 2026
31w ago
EFFECT
NEUTRAL ★ 4/10
$7.54 $4.39▼ −41.78%▼ −56.20%$2.20 (−70.82%)
Mar 11, 2026
32w ago
S-3
BEARISH ★ 7/10
$7.30 $4.68▲ +35.89%▲ +47.41%$2.20 (+69.86%)
Mar 11, 2026
32w ago
Press Release
MIXED ★ 6/10
$7.30 $4.68▼ −35.89%▼ −47.41%$2.20 (−69.86%)
Showing 9 of 9

US Market Status

Market Closed — Opens Tue (16h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026